The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones. The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.
Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and the rest of the world (RoW).
The report includes:
- 20 data tables and 26 additional tables
- An overview of the global market for immunotherapy drugs
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
- Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting the market growth
- Description of immunotherapy, combination immunotherapy and discussion on how it targets cell-mediated adaptive immunity
- Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end-user and region
- Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on the future of immunotherapy in cancer
- Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
- Discussion on fine-tuning versus boosting cancer immunity and early versus advanced-stage cancer immunotherapy
- Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of Report
- Methodology
- Market Estimates
- Information Sources
- Primary Research
- Secondary Research
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Immunotherapy
- Towards Combination Immunotherapy
- Focusing on Cell-mediated Adaptive Immunity
- Fine Tuning Vs. Boosting Cancer Immunity
- Early Vs. Advanced Stage Cancer Immunotherapy
- Personalized Treatment Paradigm
- Clinically Significant Types of Cancers
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Stomach Cancer
- Leukemia
- Future of Immunotherapy in Cancer
- Infectious Diseases
- Immunotherapy against Autoimmune Disorders
- Immunotherapies against Infectious Diseases
- Biologics as Autoimmune Disorder Therapies
- Trends in Autoimmune Disorder Therapies
- Types of Immunotherapies
- Checkpoint Inhibitors
- Unmet Medical Needs
- New Biomarkers to Stratify Patients
- Relapse/Refractory Patients
- Treatment Efficacy and Tolerability
- Innovative Strategies
- Novel Targeted Approaches
- Monoclonal Antibodies
- Interleukins
- Interferons
Chapter 4 Market Dynamics
- Strengths of Immunotherapy Market
- Growing Aging Population
- Rising Incidence of Diseases
- Patent Expirations
- Growing Pipeline
- Drive to Reduce Costs
- Government Incentives
- Collaborations and Partnerships
- Mergers and Acquisitions
- Weaknesses of the Immunotherapy Market
- Manufacturing Process
- Process Definition and Testing and Validation
- Lack of Skilled Personnel
- Regulatory Guidelines
- Patent Litigation
- Threats to Immunotherapy Market
- Unpredictable Regulatory Landscape
- Prescriptions by Medical Practitioners/Pharmacies
- Competition
- Opportunities in the Immunotherapy Market
- Emerging Markets
- Technological Innovation and Improved Process Knowledge
- Pricing
Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry
- Short-term Impact
- Change in Demand
- Shift of Communication and Promotions to Remote Interactions
- Changes to R&D
- Long-term Impact
- Delayed Approvals for Non-COVID-related Pharmaceutical Products
- Self-sufficiency in the Pharmaceutical Industry
- Changes in Consumption Trends in Health-related Products
Chapter 6 Market Breakdown by Product Type
- Overview
- Monoclonal Antibodies
- Market Overview
- Market Revenue
- Market Share
- Market by Region
- Market Overview
- Market Revenue
- Market Share
- Checkpoint Inhibitors
- Pembrolizumab
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Pembrolizumab
- Nivolumab (Opdivo)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Nivolumab
- Atezolizumab (Tecentriq)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Atezolizumab
- Avelumab (Bavencio)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Avelumab
- Durvalumab (Imfinzi)
- Companion Diagnostic
- Clinical Trial Program
- Durvalumab Forecasts
- Yervoy (Ipilimumab)
- Market by Region
- Market Revenue
- Market Share
- Interferons and Interleukins
- Market Revenue
- Market by Region
- Market by Disease Area
Chapter 7 Market Breakdown by Region
- Market Overview and Discussion
- North America
- United States
- Canada
- Europe
- Asia-Pacific
- China
- Japan
- Rest of the World
Chapter 8 Company Profiles
- Abbvie Inc.
- Amgen Inc.
- Astrazeneca
- Bayer Ag
- Bristol Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Viatris Inc. (Formerly Mylan)
- Novartis Ag
- Pfizer Inc.
- Vertex Pharmaceuticals Inc.
List of Tables
Summary Table B: Global Market for Immunotherapy Drugs, by Region, Through 2025
Summary Table A: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 1: Stages of Lung Cancer
Table 2: Biologics as Autoimmune Disorder Therapies
Table 3: Adverse Events Associated with Immune-Checkpoint Blockade
Table 4: Evolution of Monoclonal Antibodies
Table 5: Advantages and Disadvantages of Monoclonal Antibodies
Table 6: Murine Monoclonal Antibodies
Table 7: Chimeric Monoclonal Antibodies
Table 8: Humanized Monoclonal Antibodies
Table 9: Human Monoclonal Antibodies
Table 10: Selected Approved Interferon Alpha Analogs
Table 11: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 12: Global Market for Monoclonal Antibodies, by Type, Through 2025
Table 13: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Table 14: Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
Table 15: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Table 16: Global Market for Checkpoint Inhibitors, 2019-2025
Table 17: Pembrolizumab Approved Indications
Table 18: Nivolumab Approved Indications
Table 19: Atezolizumab Approved Indications
Table 20: Avelumab Approved Indications
Table 21: Durvalumab Approved Indications
Table 22: Global Market of Checkpoint Inhibitors, by Region, Through 2025
Table 23: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Table 24: Global Market for Interferons and Interleukins, Through 2025
Table 25: Global Market for Interferons and Interleukins, by Region, Through 2025
Table 26: Global Market for Immunotherapy, by Therapeutic Area, Through 2025
Table 27: Global Market for Immunotherapy Drugs, by Region, Through 2025
Table 28: North American Market for Immunotherapy Drugs, by Country, Through 2025
Table 29: North American Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 30: European Market for Immunotherapy Drugs, by Country, Through 2025
Table 31: European Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 32: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
Table 33: Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 34: Chinese Market Statistics
Table 35: Japanese Market Statistics
Table 36: AbbVie: Product Portfolio
Table 37: Amgen: Product Portfolio
Table 38: AstraZeneca: Product Portfolio
Table 39: Bayer AG: Product Portfolio
Table 40: Johnson & Johnson: Product Portfolio
Table 41: Viatris: Product Portfolio
Table 42: Novartis AG: Product Portfolio
Table 43: Pfizer: Product Portfolio
Table 44: Pfizer: Pipeline Product Portfolio
List of Figures
Summary Figure A: Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
Summary Figure B: Global Market for Immunotherapy Drugs, by Region, 2019-2025
Figure 1: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
Figure 2: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
Figure 3: Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
Figure 4: Five-Year Survival Rates, by Lung Cancer Stage
Figure 5: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
Figure 6: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
Figure 7: Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
Figure 8: Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
Figure 9: Five-Year Survival Rates, by Breast Cancer Stage
Figure 10: Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
Figure 11: Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
Figure 12: Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
Figure 13: Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
Figure 14: Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 15: Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
Figure 16: Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
Figure 17: Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
Figure 18: Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
Figure 19: Five-Year Survival Rates, by Stomach Cancer Stage
Figure 20: Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
Figure 21: Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
Figure 22: Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
Figure 23: Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
Figure 24: Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 25: SWOT Analysis of Immunotherapy Market
Figure 26: Impact of COVID-19 on the Pharmaceutical Industry
Figure 27: Global Market for Immunotherapy Drugs, 2019-2025
Figure 28: Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 29: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Figure 30: Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
Figure 31: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Figure 32: Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 33: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 34: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 35: Global Market for Pembrolizumab, 2019-2025
Figure 36: Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 37: Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 38: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 39: Global Market for Nivolumab, 2019-2025
Figure 40: Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 41: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 42: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 43: Global Market for Atezolizumab, 2019-2025
Figure 44: Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 45: Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 46: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 47: Global Market for Avelumab, 2019-2025
Figure 48: Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 49: Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 50: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 51: Global Market for Durvalumab, 2019-2025
Figure 52: Global Market for Ipilimumab, 2019-2025
Figure 53: Global Market for Checkpoint Inhibitors, by Region, 2019-2025
Figure 54: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Figure 55: Global Market for Interferons and Interleukins, by Region, 2019-2025
Figure 56: Global Market Shares for Immunotherapy Drugs, by Region, 2019
Figure 57: North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 58: European Market for Immunotherapy Drugs, by Country, 2019-2025
Figure 59: European Market for Immunotherapy Drugs, by Product Type, 2019-2025
Figure 60: Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 61: AbbVie Inc.: Annual Revenue, 2016-2019
Figure 62: AbbVie: Revenue Share, by Region/Country, 2019
Figure 63: AbbVie: Revenue Share, by Business Unit, 2019
Figure 64: Amgen: Annual Revenue, 2016-2019
Figure 65: Amgen: Revenue Share, by Region/Country, 2019
Figure 66: Amgen: Revenue Share, by Products, 2019
Figure 67: AstraZeneca: Annual Revenue, 2016-2019
Figure 68: AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 69: AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 70: Bayer AG: Annual Revenue, 2016-2019
Figure 71: Bayer AG: Revenue Share, by Region, 2019
Figure 72: Bayer AG: Revenue Share, by Business Unit, 2019
Figure 73: Bristol Myers Squibb: Annual Revenue, 2016-2019
Figure 74: Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 75: Bristol Myers Squibb: Revenue Share, by Brands, 2019
Figure 76: Hoffmann-La Roche: Annual Revenue, 2016-2019
Figure 77: Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 78: Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
Figure 79: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 80: Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 81: Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 82: Viatris: Annual Revenue, 2016-2019
Figure 83: Viatris: Revenue Share, by Region, 2019
Figure 84: Viatris: Revenue Share, by Business Unit, 2019
Figure 85: Novartis AG: Annual Revenue, 2015-2019
Figure 86: Novartis AG: Revenue Share, by Region/Country, 2019
Figure 87: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 88: Pfizer: Annual Revenue, 2016-2019
Figure 89: Pfizer: Revenue Share, by Region/Country, 2019
Figure 90: Pfizer: Revenue Share, by Business Segment, 2019
Figure 91: Vertex Pharmaceuticals: Annual Revenue, 2016-2019
Figure 92: Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
Figure 93: Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019
Samples
LOADING...
Executive Summary
By product type, the immunotherapy drugs market is divided into the following segments:
- Monoclonal antibodies
- Checkpoint inhibitors
- Interferons and interleukins
The monoclonal antibodies segment accounted for the largest share of the global market for immunotherapy drugs in 2019. This large share can be attributed to several factors including their high specificity and fewer side-effects; the increasing focus on personalized medicines; initiatives by industry players; and the growing target disease incidence and patient pool. In 2019, the market for monoclonal antibodies was $106.8 billion.
Companies Mentioned
- Abbvie Inc.
- Amgen Inc.
- AstraZeneca
- Bayer Ag
- Bristol Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Novartis Ag
- Pfizer Inc.
- Vertex Pharmaceuticals Inc.
- Viatris Inc. (Formerly Mylan)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 143 |
| Published | March 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 139.8 Billion |
| Forecasted Market Value ( USD | $ 204.4 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
